617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I

A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

A Phase I Study of Chidamide in Combination with Dcag and Venetoclax in Acute Myeloid Leukemia: Clinical Safety, Efficacy, and Correlative Analysis

Anchored Matching Adjusted Indirect Treatment Comparison of Quizartinib Vs Midostaurin in Newly Diagnosed Patients with FLT3-ITD-Positive Acute Myeloid Leukaemia

Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group

Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) As an Effective Treatment Remodels Proteostasis and Triggers Inflammatory Response in FLT3-ITD AML

Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML

Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study

Effectiveness of Olutasidenib Versus Ivosidenib in Patients with Mutated Isocitrate Dehydrogenase 1 Acute Myeloid Leukemia Who Are Relapsed or Refractory to Venetoclax: The 2102-HEM-101 Trial Versus a US Electronic Health Record-Based External Control Arm

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Safety and Efficacy of Venetoclax, Cytarabine and Metformin for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia

Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial

Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) Results in Higher Remission Rates over Conventional 7+3 Chemotherapy without Increased Toxicity in Newly Diagnosed Acute Myeloid Leukemia

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

Venetoclax Plus Idarubicin and Cytarabine Chemotherapy As First-Line Treatment for Adults with Acute Myeloid Leukaemia

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification